Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | An update on Superbugs in 2016 – Agenda released to tackle the threat of anti-microbial resistanceSMi Group is thrilled to announce that agenda has now been released for the 18th annual conference on Superbugs & Superdrugs, set to take place on 16th and 17th March 2016 in London, UK
By: SMi Group Expanding horizons on the growing global threat of anti-microbial resistance for almost two decades, Superbugs & Superdrugs will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to discuss the latest clinical advancements and funding opportunities. Working with an expert advisory board and an esteemed panel of industry leaders, the new agenda for 2016 will hone in on key topics such as R&D, collaboration, global epidemics, monoclonal anti-bodies, genome sequencing, rapid diagnostic tools, antibiotic alternatives, multi-resistance gram-negative infections, resistance prevention, antimicrobial peptides, combination therapies, microbiodata host interactions, plus much more! Featured Speakers Include: Richard Bax, Senior Partner, Transcrip Partners Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd Line Matthiessen, MD PhD, Head of Unit Fighting Infectious Diseases and Advancing Public Health, European Commission Melissa Stundick, Chief, Anti-Infectives Programme, BARDA Ursula Theuretzbacher, Founder, Centre for Anti-Infective Agents Prabhavathi Fernandes, President & CEO, Cempra Pharmaceuticals Ankit Mahadevia, MD , President & CEO, Spero Therapeutics Eszter Nagy, Co-founder, President and CSO, Arsanis Jean de Gunzburg, Chief Scientific Officer, Da Volterra David Cook, Chief Scientific Officer, Blueberry Therapeutics Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience Steven Boakes, Associate Director of Microbiology, Cantab Anti-Infectives The conference will aim to: 1. Provide networking opportunities with industry-leading experts on drug and antimicrobial material developments 2. Present new funding opportunities from BARDA to combat antimicrobial resistance 3. Discuss how the EU Commission's practical approach in R&D can support business growth 4. Look to reinvigorate business models with Project DRIVE-AB and find workable solutions to strengthen drug development 5. Build antibiotic pipelines with new insights on microbiome profiling to fight multi-resistant gram negative infections 6. Tackle major bottlenecks that hinder development of new antimicrobial drugs through interactive debate Further details can be found on the website at https://www.smi- For those who are interested in attending, a £400 early bird saving is currently available online which expires on November 30th. 18th annual conference: Superbugs & Superdrugs 16-17 March 2016 Holiday Inn Kensington Forum, London UK https://www.smi- --- END --- About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|